anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

129,241-129,300 of 319,975

filter-aware
106
The slide uses a red box to highlight the 'n=17' discrepancy in the source text.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
107
The slide uses an FDA review document to highlight a safety risk (QTc prolongation) that the company allegedly downplays.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
108
The slide uses a direct quote from a study to argue that 'malaise sensation' is a euphemism for 'fainting' (syncope) to downplay cardiotoxicity.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
109
The slide uses a table to contrast initial high-dose trials with subsequent lower-dose trials to imply company knowledge of toxicity.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
110
The slide uses a 'before-after' or 'comparison' structure to highlight the exclusion criteria in two different trial papers.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
111
The slide uses a 'villain critique' style to highlight a lack of transparency in clinical trial reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
112
The slide uses a 'fraud-exposure' narrative to highlight missing safety data in regulatory filings.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
113
The slide uses a critical tone to challenge the integrity of the reported clinical trial data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
114
The slide uses a critical tone to highlight potential data manipulation or poor reporting practices in a clinical trial publication.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
115
The slide uses a red underline to emphasize the specific clinical findings in the excerpt.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
116
The slide critiques the authors' interpretation of ECG/QTc data in the HAROSA 2 trial, pointing out potential bias or omission.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
117
Harmony Biosciences (HRMY)Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
118
The slide uses a 'black box' argument to challenge the validity of the sponsor's pharmacokinetic model.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
119
The slide uses direct quotes from the EMA's CHMP assessment report to highlight regulatory discrepancies.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
120
The slide uses a combination of narrative argument and a direct quote from a consultant to build a case against the company's transparency.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
121
The slide presents a direct quote from a PK expert to undermine the validity of the company's safety assertions.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
122
The slide uses a 'before-after' or 'comparison' logic to expose data manipulation in clinical reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
123
The slide uses a red box to highlight a specific data point (40mg dose) in a table to support the argument of inconsistent reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
124
The slide uses a specific FDA review document (NDA 211150) to challenge official plasma level claims.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
125
The slide uses a specific data table to support a broader narrative of corporate non-transparency regarding PK data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
126
The slide uses a table to expose data inconsistencies and safety risks, framing the variability as a 'red flag' regarding the drug's safety profile.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
127
The slide uses a '>' prefix, suggesting it is a direct, provocative assertion or a 'villain' critique.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
128
The slide uses a direct quote from an FDA clinical review to contradict the company's safety claims, supported by a table of clinical data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
129
The slide highlights the safety margin between the recommended dose (40mg) and the doses where QTc prolongation was observed (120-240mg), while noting specific patient populations at higher risk.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
130
The slide uses direct citations from FDA and research documents to highlight the discrepancy between single-dose study designs and the need for steady-state peak plasma concentration analysis.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
131
The slide uses a quote from a pharmacology consultant to argue that safety margins are overestimated due to drug accumulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
132
The slide highlights a specific discrepancy in an FDA review document (page 32) where the graph title claims 'steady state Cmax' but the underlying data is from a single dose.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
133
The slide uses a red box to highlight the specific column in the table containing the erroneous data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
134
The slide documents the source data used by a consultant to derive a linear regression model for QTc vs. plasma levels.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
135
The slide uses a 'before-after' logic to expose a flaw in regulatory reliance on single-dose data. The red box highlights the critical 'Upper limit TQT' values in the corrected table.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
136
Includes a linear regression equation Y=14.62*X+53.34 and a scatter plot with error bars.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
137
Harmony Biosciences (HRMY)Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
138
The slide uses direct excerpts from the drug's prescribing information to build a case against its safety profile.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
139
The slide uses a direct excerpt from a package insert to support the argument that dose reduction is required due to drug interactions.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
140
The slide uses a quote from a consultant to challenge the validity of the company's (Harmony) data submitted to the FDA.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
141
The slide uses direct citations from peer-reviewed papers to validate the consultant's findings.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
142
The slide uses direct excerpts from regulatory documents to challenge the company's claims regarding drug safety and pharmacokinetics.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
143
The slide uses a ClinicalTrials.gov entry as evidence of a 'buried' or incomplete study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
144
The slide uses a Wikipedia table to demonstrate the complexity of CYP2D6 phenotypes to undermine the validity of the FDA's small-sample study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
145
The slide contrasts the author's critique with a direct excerpt from an FDA Clinical Pharmacology Review.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
146
The slide uses a 'red flag' narrative to challenge the integrity of clinical trial data reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
147
The slide uses direct excerpts from FDA documents and product labels to highlight a contradiction in clinical trial methodology.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
148
The slide uses a combination of narrative argument and a supporting data table to challenge the safety profile of the drug.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
149
The slide uses regulatory documents (EMA/FDA) and primary research (prescriber interviews) to build a case for potential safety risks.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
150
The slide uses a specific calculation (153 ng/mL * 4 * 2 = 1224 ng/mL) to quantify risk.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
151
Uses anecdotal evidence from Facebook patient support groups to highlight a safety gap.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
152
The slide uses red underlining to highlight specific dangerous medical advice given to patients.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
153
Harmony Biosciences (HRMY)Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
154
The slide uses a 'villain critique' style to frame the FDA's approval as flawed and the drug's safety as compromised.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
155
The slide uses a narrative summary followed by a supporting table (Table 4) to challenge the safety reporting of the drug.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
156
The slide uses a combination of narrative analysis and a specific case study excerpt to challenge the safety profile of pitolisant.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
157
The slide presents clinical case summaries to address potential safety concerns regarding cardiac events.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
158
The slide uses direct quotes from FDA clinical reviews to highlight the discrepancy between pre-approval assumptions and post-approval safety signals.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
159
Harmony Biosciences (HRMY)Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
160
The slide highlights the FDA's 'wait-and-see' posture and specific concerns about seizures as a safety signal for the drug pitolisant.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
161
The slide uses a 'fraud-exposure' or 'investigative' tone to question the lack of public data on a specific study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
162
Harmony Biosciences (HRMY)Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
163
The slide uses a 'villain' narrative to frame the company's non-disclosure as intentional concealment.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
164
The slide uses a combination of original analysis and cited medical literature to challenge the transparency of clinical trial reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
165
The slide uses a 'preempt_rebuttal' strategy by highlighting a specific safety concern (eosinophilic abnormality) that the authors claim was ignored in official FDA review documents.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit